Clinical Trial Update: A Study of Galunisertib in Participants With Myelodysplastic Syndromes [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating galunisertib in myelodysplastic syndromes has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Galunisertib (galunisertib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Myelodysplastic Syndromes | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-03-07